Building effective collaborations for the study of COVID-19 across the severity spectrum

Nat Immunol. 2022 Sep;23(9):1287-1290. doi: 10.1038/s41590-022-01283-2.

Roseline S Agyekum^{1

2}, Benjamin A Abramoff³, E John Wherry^{4

5

6}, Nuala J Meyer^{7

8

9}

¹ Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
² Center for Translational Lung Biology, Lung Biology Institute, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
³ Department of Physical Medicine and Rehabilitation, , University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
⁴ Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
⁵ Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
⁶ Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
⁷ Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA. [email protected].
⁸ Center for Translational Lung Biology, Lung Biology Institute, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA. [email protected].
⁹ Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA. [email protected].

No abstract available

MeSH terms